A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia

Trial Profile

A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Cytarabine (Primary) ; Ibrutinib (Primary) ; Idarubicin (Primary)
  • Indications Myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2017 Status changed from recruiting to discontinued.
    • 24 Aug 2017 Status changed from suspended to recruiting.
    • 24 Apr 2017 Status changed from recruiting to suspended due to Regulatory.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top